Attributable Failure of First-line Cancer Treatment and Incremental Costs Associated With Smoking by Patients With Cancer

Warren, Graham; Cartmell, Kathleen B.; Garrett‐Mayer, Elizabeth; Salloum, Ramzi G.; Cummings, K. Michael

doi:10.1001/jamanetworkopen.2019.1703

Cited by 58 publications

(51 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Continued tobacco use by cancer patients not only increases the risk for adverse cancer treatment outcomes,[1] but also significantly increases the cost of subsequent cancer treatment. [2] This study underscores the need for the integration of tobacco dependence treatment strategies in cancer care settings. [20–22] It also provides clinicians in cancer care settings with population-based benchmark estimates of cigarette and non-cigarette tobacco product use among cancer survivors.…”

Section: Discussionmentioning

confidence: 92%

“…[1] Tobacco use has also been associated with poorer response to cancer treatment and cancer recurrence leading to significantly increased costs associated with cancer treatment. [2] Cigarette smoking rates among cancer survivors have been reported in prior studies using two national data sources. First, using the National Health Interview Survey (NHIS), current smoking prevalence among cancer survivors was 20.2% in a study that combined four waves of the NHIS (1998–2001).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Tobacco and E-cigarette use among cancer survivors in the United States

et al. 2019

Self Cite

View full text Add to dashboard Cite

BackgroundLimited information exist on tobacco and e-cigarette use patterns in cancer survivors. The purpose of this study is to report on use patterns in cancer survivors compared with non-cancer participants from the Population Assessment of Tobacco and Health (PATH) Study.MethodsSociodemographic data and tobacco product use were analyzed for 32,244 adult participants from the PATH Study in 2013–2014 by cancer status and age. Logistic regression examined the patterns of and factors associated with tobacco use by cancer status.ResultsOverall, cancer survivors represented 7.1% (n = 1,527) of participants, were older, and had a higher proportion of females and non-Hispanic whites than non-cancer participants. In cancer survivors, current and former cigarette smoking was reported in 12.7% and 32.9% respectively, compared with 18.5% and 19.0% in non-cancer adults. Current e-cigarette use was reported by 3.8% of survivors compared with 5.7% of non-cancer participants. Dual tobacco use was reported by 25.0% and poly use by 6.9% of cancer survivors who currently smoked. All other forms of current tobacco use were individually reported by <5% of survivors. Young adult cancer survivors (aged 18–44) reported the highest rates of current cigarette smoking (27.9%) and current e-cigarette use (11.8%). The effects of age, sex, race/ethnicity, education, and income on tobacco use status were comparable for cancer survivors and non-cancer participants. Cancer survivors who were younger, male, of lower educational attainment, and those diagnosed with a tobacco-related cancer were more likely to report current tobacco use.ConclusionsAmong cancer survivors, cigarette smoking remains the predominant form of tobacco use, although other tobacco/nicotine use and dual/poly use are common. The PATH Study provides detailed tobacco product use patterns in survivors, including their adoption of emerging alternative tobacco products.

show abstract

Section: Discussionmentioning

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Tobacco and E-cigarette use among cancer survivors in the United States

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…For example, the average annual program costs to treat new and returning patients is $800 to $1000, with a cost per quit of $1900 to $2500, which, in the context of cancer care, seems well justified. 40…”

Section: Discussionmentioning

confidence: 99%

Association of a Comprehensive Smoking Cessation Program With Smoking Abstinence Among Patients With Cancer

et al. 2019

View full text Add to dashboard Cite

Key PointsQuestionAre there differences in abstinence rates between patients with and without cancer after treatment in a comprehensive tobacco cessation program delivered in an oncologic setting?FindingsIn this cohort study of 3245 smokers in a tobacco treatment program, mean smoking abstinence rates were 45.1% at the 3-month follow-up, 45.8% at the 6-month follow-up, and 43.7% at the 9-month follow-up; rates did not differ between patients with and without cancer. Patients with head and neck cancer were among those with the highest abstinence rates.MeaningWhen exposed to a comprehensive tobacco treatment program, smokers with and without cancer showed sustained high quit rates and did not differ from each other, suggesting that comprehensive treatment in an oncologic setting may be successful.

show abstract

“…3,22 Additionally, a recent report has shown a potential $3.4 billion incremental cost of treating cancer failures associated with continued smoking among patients with cancer in the United States each year. 23 As such, most leading cancer organizations, including the International Association for the Study of Lung Cancer (IASLC), strongly endorse advising patients to quit smoking and establishing evidence-based tobacco treatment delivery as an indicator of high-quality cancer care. [24][25][26] Although a recent lung cancer provider survey conducted by IASLC showed strong endorsement for the importance of smoking cessation for cancer patients, it has not yet been adopted widely as a standard of care.…”

Section: Lung Cancer Treatment and Smoking Cessationmentioning

confidence: 99%

Prevention and Early Detection for NSCLC: Advances in Thoracic Oncology 2018

Balata

Fong

Hendriks

et al. 2019

Journal of Thoracic Oncology

View full text Add to dashboard Cite

Lung cancer remains the leading cause of cancer-related mortality worldwide. Tobacco consumption remains the most important risk factor. Although the prevalence of smoking has decreased overall, it continues to be a significant burden for global health. It is estimated that there are still nearly 1 billion cigarette smokers worldwide. Prevention strategies have largely focused on tobacco control and prevention. However, we have witnessed a dramatic increase in the use of e-cigarettes and other vaping products. Primary chemoprevention has historically not been a successful strategy for lung cancer; however, focused approaches in specific groups of patients at high risk for development of lung cancer are underway. The majority of cases with NSCLC are diagnosed with locally advanced or metastatic disease, where the overall prognosis remains very poor. Early-stage NSCLC on the other hand has a much better prognosis and can usually be treated radically with either surgical resection or radical radiotherapy, with relatively favorable long-term outcomes. In addition to image-based screening, other methods such as breath-based and biofluidbased approaches are now being investigated for early detection of NSCLC. This review will focus on recent advancements in the field of prevention, screening, and early detection of NSCLC.

show abstract

Attributable Failure of First-line Cancer Treatment and Incremental Costs Associated With Smoking by Patients With Cancer

Abstract: This economic evaluation models incremental costs of subsequent cancer treatment after failure of first-line cancer treatment among smoking vs nonsmoking patients with cancer.

Cited by 58 publications

References 27 publications

Tobacco and E-cigarette use among cancer survivors in the United States

Tobacco and E-cigarette use among cancer survivors in the United States

Association of a Comprehensive Smoking Cessation Program With Smoking Abstinence Among Patients With Cancer

Prevention and Early Detection for NSCLC: Advances in Thoracic Oncology 2018

Contact Info

Product

Resources

About